Salbutamol,
    Suppliers, Fact sheet, Application, Reports, Datasheet, Patent, Suppliers, Market
                                                               Primary Information Services                                                      
Home. Pharmaceutical Industry .Ordering Information. Contact 

Project at a Glance

Contents on the CD Rom

• Salbutamol (INN) or albuterol (USAN) is a short-acting β2-adrenergic receptor agonist used for the relief of bronchospasm in conditions such as asthma and chronic obstructive pulmonary disease.
• It is marketed as Ventolin among other brand names.
• Salbutamol was the first selective β2-receptor agonist to be marketed — in 1968.
• It was first sold by Allen & Hanburys under the brand name Ventolin.
• The drug was an instant success, and has been used for the treatment of asthma ever since.
• Salbutamol sulfate is usually given by the inhaled route for direct effect on bronchial smooth muscle.
• This is usually achieved through a metered dose inhaler (MDI), nebulizer or other proprietary delivery devices (e.g. Rotahaler or Autohaler).
• In these forms of delivery, the maximal effect of salbutamol can take place within five to twenty minutes of dosing, though some relief is immediately seen.
• It can also be given orally as an inhalant or intravenously.
• Salamol is, like Ventolin, a brand of salbutamol and is bioequivalent.
• Salamol is also widely used internationally, having been approved in the United States and the United Kingdom.
• In the United Kingdom,  Salamol has been registered and prescribed for over four years and has a significant share of the salbutamol market there, with over 600,000 units being dispensed each month.
• There is nothing to compare this product’s introduction with fenoterol’s safety concerns.
• The usual dose to relieve asthma symptoms is 1 to 2 inhalations (also called "puffs") for people 12 years of age and older, and 1 puff for children 6 to 11 years of age.
• It is not known if the response to higher doses of nebulised beta-agonists
  or other bronchodilators is impaired.
• We assessed the effect of long-acting beta-agonist treatment on the response to 5 mg nebulised salbutamol and to ipratropium bromide.
• The response to nebulised salbutamol was 15% lower after formoterol therapy compared to placebo (95% confidence 5 to 25%, p = 0.008).
• Patients using long-acting beta-agonists may respond less well to emergency beta-agonist treatment.
• Additional treatment with an alternative bronchodilator should be considered early in the course of an exacerbation

Research

• Formulation and evaluation of salbutamol sulphate fast dissolving tablet
• The study of salbutamol matrix tablets using different polymers as release retarding agent
• Investigations on the Humidity-Induced Transformations of Salbutamol Sulphate Particles Coated with L-Leucine
• Overcoming beta-agonist tolerance: high dose salbutamol and ipratropium bromide. Two randomised controlled trials

Order the CD ROM Today

Primary Information Services
 21 Murugappan St, SwamyNagar Ext2, 
Ullagaram, Chennai - 600091, India.
 Phone: 91 44 22421080  Email : informer@eth.net
Mobile numbers:9940043898, 9444008898  Fax : 91 44 22423753